UY34465A - ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?. - Google Patents

?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?.

Info

Publication number
UY34465A
UY34465A UY0001034465A UY34465A UY34465A UY 34465 A UY34465 A UY 34465A UY 0001034465 A UY0001034465 A UY 0001034465A UY 34465 A UY34465 A UY 34465A UY 34465 A UY34465 A UY 34465A
Authority
UY
Uruguay
Prior art keywords
alfa1
progression
beginning
delay
proteinase inhibitor
Prior art date
Application number
UY0001034465A
Other languages
English (en)
Inventor
Forshag Mark
Waltrip Royce
Garlinghouse Les
Barnett William
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY34465A publication Critical patent/UY34465A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen procedimientos para demorar el comienzo o disminuir la progresión de exacerbaciones pulmonares mediante la administración de inhibidor de alfa1-proteinasa inhalado.
UY0001034465A 2011-12-30 2012-11-23 ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?. UY34465A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161581708P 2011-12-30 2011-12-30

Publications (1)

Publication Number Publication Date
UY34465A true UY34465A (es) 2013-07-31

Family

ID=47470050

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034465A UY34465A (es) 2011-12-30 2012-11-23 ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?.

Country Status (18)

Country Link
US (1) US9421248B2 (es)
EP (1) EP2758065B1 (es)
JP (4) JP2015504051A (es)
KR (1) KR20140108516A (es)
CN (2) CN103889436A (es)
AR (2) AR088971A1 (es)
AU (1) AU2012337241B2 (es)
BR (1) BR112014007127A2 (es)
CA (1) CA2844878C (es)
CL (1) CL2014000722A1 (es)
ES (1) ES2887358T3 (es)
IL (1) IL231109B (es)
MX (1) MX351189B (es)
MY (1) MY166314A (es)
RU (1) RU2635482C2 (es)
SG (2) SG2014012066A (es)
UY (1) UY34465A (es)
WO (1) WO2013098672A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3030254A2 (en) * 2013-08-05 2016-06-15 Gerard Voerman Novel means to decrease the negative effects of smoking
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
RS65152B1 (sr) * 2015-02-05 2024-02-29 Canem Holdings Llc Preparati za lečenje granulomatoze sa poliangiitisom
CA3054267A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
US10663434B2 (en) * 2017-03-31 2020-05-26 Sonix, Inc. Wafer chuck
CA3106151A1 (en) * 2018-07-10 2020-01-16 Christopher V. Ciancone Breath measurement device
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
TW202122086A (zh) * 2019-08-23 2021-06-16 韓商Ｐｈ製藥公司 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
EP4142775B1 (en) * 2020-05-01 2026-03-25 Ageronix SA Treatment and/or prevention of a disease or a syndrome related to a virus infection

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE395611B (sv) 1975-12-12 1977-08-22 Draco Ab Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser
SE411705B (sv) 1976-11-09 1980-02-04 Draco Ab Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4667688A (en) 1983-11-28 1987-05-26 Francisco Roig Mini pack of cigarettes
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
DE3581328D1 (de) 1984-06-19 1991-02-21 Transgene Sa Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung.
US4697003A (en) 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US5114917A (en) 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
WO1997009350A1 (en) 1995-09-07 1997-03-13 Ppl Therapeutics (Scotland) Ltd. Purification of alpha-1 proteinase inhibitor
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
RO121834B1 (ro) 1998-03-16 2008-06-30 Inhale Therapeutic Systems, Inc. Dispozitiv pentru administrarea unui agent activ
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
EP1366175B1 (en) 2000-12-18 2008-01-23 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
WO2005027821A2 (en) 2003-09-22 2005-03-31 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
JP2007511539A (ja) 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
CA2559062A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
ES2399449T3 (es) * 2006-02-09 2013-04-01 Kamada Ltd. Administración pulmonar de un inhibidor de proteinasa alfa-1
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
CA2730018A1 (en) 2008-07-18 2010-01-21 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
TR201809898T4 (tr) 2009-11-03 2018-07-23 Grifols Therapeutics Llc Alfa-1 protei̇naz i̇nhi̇bi̇törüne yöneli̇k bi̇leşi̇m, yöntem ve ki̇t.

Also Published As

Publication number Publication date
AR088971A1 (es) 2014-07-23
JP2015504051A (ja) 2015-02-05
NZ621596A (en) 2016-08-26
JP2017039745A (ja) 2017-02-23
MX351189B (es) 2017-10-04
MX2014001764A (es) 2014-04-30
CA2844878C (en) 2017-11-28
RU2635482C2 (ru) 2017-11-13
AR116887A2 (es) 2021-06-23
CA2844878A1 (en) 2013-07-04
IL231109A0 (en) 2014-04-30
AU2012337241B2 (en) 2016-10-13
CL2014000722A1 (es) 2014-10-10
SG2014012066A (en) 2014-09-26
WO2013098672A3 (en) 2013-10-24
EP2758065B1 (en) 2021-06-23
MY166314A (en) 2018-06-25
KR20140108516A (ko) 2014-09-11
EP2758065A2 (en) 2014-07-30
US9421248B2 (en) 2016-08-23
IL231109B (en) 2018-02-28
RU2014106758A (ru) 2015-08-27
BR112014007127A2 (pt) 2017-04-04
JP2018104439A (ja) 2018-07-05
WO2013098672A2 (en) 2013-07-04
CN103889436A (zh) 2014-06-25
ES2887358T3 (es) 2021-12-22
CN107596359A (zh) 2018-01-19
AU2012337241A1 (en) 2013-07-18
US20150011460A1 (en) 2015-01-08
SG10201610913PA (en) 2017-02-27
HK1198918A1 (en) 2015-06-19
JP2019135243A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
CR20150507A (es) Inhibidores de histona desmetilasas
SMT201700109B (it) Inibitori di istone demetilasi
UY34465A (es) ?inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares?.
BR112013028235A2 (pt) refrigerador
EP2914263A4 (en) ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
CR20140024A (es) Compuestos inhibidores de metaloenzimas
BR112013028281A2 (pt) compostos e composições para inibição de nampt
ZA201506452B (en) 3-pyrimidin-4-yl-oxazolidin -2-ones as inhibitors of mutant idh
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
TWD180147S (zh) 淨水器
SI3715345T1 (sl) Priprava zaviralca lfa-1
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
PT3628670T (pt) Forma salina de um inibidor de ezh2
HUE053047T2 (hu) MDM2 inhibitor kristályos formája
HUE053112T2 (hu) PDE 4 inhibitor kristályos formája
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
EP2933248A4 (en) NOVEL RENIN INHIBITOR
DK3562487T3 (da) Metalloenzyminhibitorforbindelser
HUE058802T2 (hu) RIPK1 inhibitorokként alkalmas vegyületek
IL240593A0 (en) Novel inhibitory compounds of type a10 phosphodiesterase
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
IL240763B (en) The halopyrazoles as thrombin inhibitors
PL2908313T3 (pl) Adaptacyjny podział współczynnika kształt - wzmocnienie
SMT201800593T1 (it) Inibitore per disturbi retinocoroidei

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211014